How safe are 1440 nm non-ablative fractional lasers, including on darker skin?
Short answer
This 2025 review of clinical studies on a 1440/1927 nm non-ablative fractional diode laser found expected reactions such as redness, swelling and crusting were mild to moderate and resolved on their own. Discomfort and heat were mild, no serious adverse events were reported, and safety was also shown in patients with skin of colour.
- Study
- Geronemus RG, Wang JV, Jacobson AA, et al. J Cosmet Dermatol. 2025;24(11):e70523.
- Design
- Literature review
- People
- Review of published studies
- Topic
- Skin resurfacing safety
Why it matters
1440 nm is the wavelength used by Tria FRX. This review collects safety data on in-clinic lasers at that wavelength.
What they did
- Searched PubMed for clinical studies of 1440 nm and 1927 nm non-ablative fractional diode laser treatment.
- Summarised reported skin reactions, discomfort, adverse events and satisfaction.
What they found
- Redness, swelling and crusting were mild to moderate and self-limited.
- No serious adverse events were reported, including in skin of colour.
- Non-ablative fractional lasers carry less risk of scarring and pigment changes than ablative lasers.
What it cannot tell you
- Narrative review of one clinic laser system, not home devices.
- The abstract does not report how many studies or patients were included.
- Review conclusions depend on the quality of included studies.
Takeaway
At clinic level, 1440 nm non-ablative fractional treatment has a reassuring safety record across skin types. Home devices deliver less energy, which generally lowers risk further.
Matching devices
Devices whose published technology match this study: MimiSilk Iris and Tria FRX. None of them was the device tested unless the study names it.
Not medical advice. Summary based on the published abstract; read the full paper for detail.